Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Maurice Winn who wrote (2443)	8/17/1998 8:54:00 AM
From: dwight martin	Respond to of 3702

Monday August 17, 8:13 am Eastern Time Company Press Release Techniclone to Submit Phase II TNT Protocol to FDA Phase I Interim Results to be Released Shortly TUSTIN, Calif.--(BUSINESS WIRE)--Aug. 17, 1998--Techniclone Corporation (NASDAQ:TCLN - news) a developer of leading-edge unique therapeutics for the advanced treatment of cancer, announced today that it expects to shortly submit a Phase II protocol request to the FDA for its Tumor Necrosis Therapy (TNT) in malignant glioma (brain cancer) patients. The Phase II trials will be conducted at the Medical University of South Carolina (MUSC), plus three additional centers. The Company expects to commence enrollment of patients for this Phase II clinical trial by the end of this calendar year. The Company also announced that it expects to shortly release the interim results of the Phase I clinical trial for the treatment of malignant glioma with TNT. Dr. Sunil Patel, Assistant Professor of Neurological Surgery at MUSC plans to submit an abstract of the full results of the Phase I clinical trial for presentation at the American Society for Neuro-Oncology, November 12-15, in San Francisco. ''Techniclone believes that TNT has both the therapeutic and market potential for broad applications,'' stated Larry O. Bymaster, President and Chief Executive Officer of Techniclone. ''We are committed to aggressively moving forward in clinical trials for TNT, in addition to expanding TNT to other cancer applications, commencing with the recently announced clinical trial in Mexico.'' TNT Background: TNT agents act by binding to intracellular components of dead and dying cells at the core of most solid tumors and killing the cancerous tissue from the inside out. After several years of testing Techniclone believes TNT may have broad applicability to a variety of types of cancerous solid tumors due to its unique cellular binding characteristics. Data shows that most solid tumors can be imaged by TNT agents. Safe Harbor Statement: This release may contain certain forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ from the Company's expectations as a result of risk factors discussed in Techniclone's reports on file with the U.S. Securities and Exchange Commission, including, but not limited to, the Company's report on Form 10K for the year ended April 30, 1998. Company Overview: Techniclone Corporation is engaged in the research and development of unique therapeutics for the treatment of cancer. The Company utilizes innovative targeting technologies to develop products capable of destroying cancerous tumors throughout the body. Presently in Phase I clinical testing, the Company's Tumor Necrosis Therapy (TNT) is designed to deliver high doses of radiation directly to the core of the tumor while causing no damage to surrounding tissue. Oncolym(R), a therapy for the treatment of advanced B-Cell Non-Hodgkin's Lymphoma, is currently undergoing Phase II/III human testing. The Company is also developing two additional technologies for the treatment of solid tumors, Vasopermeation Enhancement Agents (VEA) and Vascular Targeting Agents (VTA). VEAs act on tumors to increase the concentration of conventional chemotherapy in the tumor site while VTAs attach to tumor blood vessels creating a blood clot which kills the tumor by eliminating its oxygen and nutrient supply. Additional information on the Company and its products can be found at www.techniclone.com. -----------------------------------------------------------------------